HomeInsightsStock Comparison

Indoco Remedies Ltd vs Marksans Pharma Ltd Stock Comparison

Indoco Remedies Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: Dec 18, 2025

Key Highlights

  • The Latest Trading Price of Indoco Remedies Ltd is ₹ 238.3 as of 18 Dec 15:30.
  • The P/E Ratio of Indoco Remedies Ltd changed from 79.9 on March 2020 to -29.2 on March 2025 . This represents a CAGR of NaN% over 6 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 26.5 on March 2025 . This represents a CAGR of 33.41% over 6 years.
  • The Market Cap of Indoco Remedies Ltd changed from ₹ 1929 crore on March 2020 to ₹ 2152 crore on March 2025 . This represents a CAGR of 1.84% over 6 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 10076 crore on March 2025 . This represents a CAGR of 61.45% over 6 years.
  • The revenue of Indoco Remedies Ltd for the Sep '25 is ₹ 485.43 crore as compare to the Jun '25 revenue of ₹ 441.3 crore. This represent the growth of 10% The revenue of Marksans Pharma Ltd for the Sep '25 is ₹ 741.98 crore as compare to the Jun '25 revenue of ₹ 625.63 crore. This represent the growth of 18.6%.
  • The ebitda of Indoco Remedies Ltd for the Sep '25 is ₹ 43.28 crore as compare to the Jun '25 ebitda of ₹ 19.16 crore. This represent the growth of 125.89% The ebitda of Marksans Pharma Ltd for the Sep '25 is ₹ 166.07 crore as compare to the Jun '25 ebitda of ₹ 105.76 crore. This represent the growth of 57.03%.
  • The net profit of Indoco Remedies Ltd changed from ₹ 24.18 crore to ₹ -9.21 crore over 10 quarters. This represents a CAGR of NaN% The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 99.14 crore over 10 quarters. This represents a CAGR of 14.65% .
  • The Dividend Payout of Indoco Remedies Ltd changed from 11.4 % on March 2020 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 6 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 19.26 % on March 2025 . This represents a CAGR of 10.12% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Indoco Remedies Ltd

  • Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
  • The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
  • The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Indoco Remedies Ltd News Hub

News

Indoco Remedies Q2 net loss narrows to Rs 9 cr

Revenue from operations stood at Rs 471.83 crore in the second quarter of FY26, up 9.59% a...

Read more

06 Nov 2025 13:20

News

Indoco Remedies to discuss results

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 6 November...

Read more

14 Oct 2025 17:34

News

Indoco Remedies enters into sale and lease back for its movable properties

Indoco Remedies has entered into a Sale Agreement and Lease Agreement on 29 August 2025 fo...

Read more

30 Aug 2025 11:44

News

Indoco Remedies AGM scheduled

Indoco Remedies announced that the Annual General Meeting(AGM) of the company will be held...

Read more

16 Aug 2025 17:23

News

Indoco Remedies receives USFDA approval for Rivaroxaban Tablets

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application...

Read more

13 Aug 2025 09:54

News

Indoco Remedies gains on receiving USFDA nod for Rivaroxaban tablets

The approval covers strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved tablets are...

Read more

13 Aug 2025 10:30

Marksans Pharma Ltd News Hub

News

Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

20 Nov 2025 14:00

News

Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Ma...

Read more

19 Nov 2025 11:32

News

Marksans Pharma's arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tabl...

Read more

19 Nov 2025 13:30

News

Relonchem receives UK MHRA's marketing approval for two products

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

17 Nov 2025 11:38

News

Marksans Pharma's Goa unit clears USFDA inspection

Marksans Pharma announced that a current Good Manufacturing Practice (cGMP) inspection was...

Read more

10 Nov 2025 14:08

News

Marksans Pharma gains after USFDA clears Goa facility with zero observations

In a filing exchange filing, the company stated that the inspection was carried out at its...

Read more

10 Nov 2025 13:03

SWOT Analysis Of Indoco Remedies Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Indoco Remedies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Indoco Remedies Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Indoco Remedies Ltd or Marksans Pharma Ltd?

Market cap of Indoco Remedies Ltd is 2,198 Cr while Market cap of Marksans Pharma Ltd is 8,224 Cr

What are the key factors driving the stock performance of Indoco Remedies Ltd and Marksans Pharma Ltd?

The stock performance of Indoco Remedies Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Indoco Remedies Ltd and Marksans Pharma Ltd?

As of December 18, 2025, the Indoco Remedies Ltd stock price is INR ₹238.3. On the other hand, Marksans Pharma Ltd stock price is INR ₹181.5.

How do dividend payouts of Indoco Remedies Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Indoco Remedies Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions